Power Law company profile

SanegeneBio

Biotech & Life Sciences · Woburn, United States · Founded 2021

SanegeneBio is an emerging biotechnology company specializing in RNA interference (RNAi) therapeutics. The company focuses on developing innovative RNAi-based drugs, particularly for chronic metabolic diseases. SanegeneBio operates in the biopharmaceutical market and serves clients in the healthcare and medical research sectors. The company employs a business model centered on research and development, clinical trials, and strategic collaborations. Revenue is generated through partnerships, licensing agreements, and the commercialization of its proprietary RNAi therapeutics. Notably, SanegeneBio has made significant strides in clinical development, with its first RNAi drug approved for clinical trials in China and ongoing Phase I trials in Australia. The company is headquartered in Suzhou and has recently moved into Phase III of BioBAY, a prominent biopharmaceutical hub. Key personnel include Dr. Jin Yuyan, who leads clinical and non-clinical development, bringing extensive experience from her tenure at Pfizer and Roche. Keywords: RNAi therapeutics, chronic metabolic diseases, clinical trials, biopharmaceutical, drug development, RNA interference, healthcare, medical research, strategic collaborations, innovative drugs.

Valuation

$100–500M

Latest valuation · 2025

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Total funding● Pre-IPO

$100–500M

Unlock exact value

Investors

21 investors on SanegeneBio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 21 investors entered at this stage

TF Capital

Yuansheng BioVenture

TEDA Venture Capital

Xiamen C&D Emerging Industry Equity Investment

Lingang Blue Bay Fund

Tencent

Shenzhen Capital Group

Oriza Holdings

Qiming Venture Partners

K2VC

Alwin Capital

SHC Shanghai Biomedical Fund

Northern Lights Venture Capital

Legend Capital

Vivo Capital

NLVC

Invus

Eli Lilly

Sino Biopharmaceutical

Lake Bleu Capital

K2 Venture Partners

Global footprint

Where SanegeneBio has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States82.6%

🇨🇳 China17.4%

2 countries shown

Talent graph

The shape of SanegeneBio's talent

Dealroom maps SanegeneBio's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

1 team members profilednamed & role-tagged by Dealroom

32 employeestotal headcount

1 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock SanegeneBio's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about SanegeneBio

An AI-synthesized read of the highest-engagement posts about SanegeneBio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SanegeneBio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles